John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.
John A. Abraham, MD, FACS
Advertisement
Articles by John A. Abraham, MD, FACS
John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.
John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.
John A. Abraham, MD, FACS, discusses the surgical management of patients with tenosynovial giant cell tumor.
John A. Abraham, MD, FACS, discusses future research efforts in tenosynovial giant cell tumor.
John A. Abraham, MD, FACS, discusses key considerations regarding the management of tenosynovial giant cell tumor.
John A. Abraham, MD, FACS, discusses potential symptoms of tenosynovial giant cell tumor.
Advertisement
Latest Updated Articles
Dr. Abraham on Surgical Improvements in TGCTPublished: November 5th 2020 | Updated:
Dr. Abraham on Remaining Questions With Pexidartinib in TGCTPublished: October 21st 2020 | Updated:
Dr. Abraham on the Surgical Management of TGCTPublished: October 2nd 2020 | Updated:
Dr. Abraham on Potential Symptoms of TGCTPublished: April 30th 2020 | Updated:
Dr. Abraham on the Clinical Utility of Pexidartinib in TGCTPublished: October 20th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5